{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004579","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.686690+00:00","generated_at":"2026-05-28T04:17:44.521726+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Geron expects Q4 RYTELO revenue ~$45-46M; FY 2024 opex ~$250-260M, cash ~$500M","bullets":["Preliminary Q4 2024 U.S. RYTELO net revenue expected $45M-$46M, first full quarter of launch.","FY 2024 operating expenses estimated ~$250M-$260M; cash, equivalents, and securities ~$500M as of Dec 31, 2024.","Estimates are preliminary, unaudited, subject to change upon completion of financial close and audit.","RYTELO (imetelstat) is Geron's approved telomerase inhibitor for lower-risk myelodysplastic syndromes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004579","json":"https://secwatch.observer/filing/0000950170-25-004579.json","markdown":"https://secwatch.observer/filing/0000950170-25-004579.md","text":"https://secwatch.observer/filing/0000950170-25-004579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017025004579/0000950170-25-004579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017025004579/gern-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:17:44.521726+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}